{
    "clinical_study": {
        "@rank": "72150", 
        "arm_group": [
            {
                "arm_group_label": "Ergoferon (5 ml 3 times a day)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo (5 ml 3 times a day)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is:\n\n        -  to assess safety of the liquid dosage form of Ergoferon for treatment of acute upper\n           respiratory tract infections in children;\n\n        -  to assess clinical efficiency of the liquid dosage form of Ergoferon for treatment\n           acute upper respiratory tract infections in children."
        }, 
        "brief_title": "Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Upper Respiratory Tract Infections", 
        "condition_browse": {
            "mesh_term": "Respiratory Tract Infections"
        }, 
        "detailed_description": {
            "textblock": "The overall duration of a patient's participation in the trial is 6 days\n      (screening/randomization, therapy onset - day 1; study therapy period - 5 days; follow-up\n      period-1 day)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients of both sexes aged over 3 years and under 18 years.\n\n          2. Patients who consulted a doctor within 24 hours after the onset of acute respiratory\n             infection (body temperature no less than 38.0\u00b0C when visiting a doctor + intensity of\n             symptoms \u2265 4  scores (presence of at least 1 general symptom \u2265 2 scores and 1 nasal/\n             throat/ chest symptom \u2265 2 scores or greater number of symptoms with the intensity\u22651\n             score) during seasonal morbidity.\n\n          3. The possibility to start therapy within 24 hours after  the onset of the first\n             symptoms of acute respiratory infection.\n\n          4. Usage of contraceptive methods by sexually active teenagers of both sexes during the\n             trial and within 30 days after ending of the participation in the trial.\n\n          5. Availability of  information sheet (Informed Consent form) for parents/adopters of\n             patient for participation in the clinical trial, Version 2.1 or Version 2.2, signed\n             by one parent/adopter of patient. For patients over 14 years - availability of\n             information sheet (Informed Consent form)  for participation in the clinical trial,\n             Version 2.1 or Version 2.2, signed by a patient and one parent/adopter of patient.\n\n        Exclusion Criteria:\n\n          1. Suspected bacterial infection or presence of a severe disease requiring use of\n             antibacterial drugs (including sulfanilamides).\n\n          2. Suspected initial manifestations of diseases that have symptoms similar to acute\n             respiratory infection (other infectious diseases, influenza-like syndrome at the\n             onset of systemic connective tissue disorders, oncohematology and other pathology).\n\n          3. Medical history of primary and secondary immune deficiency: a) lymphoid system\n             immunodeficiency (T-cell and /or B-cell immunity chain, immunodeficiency with\n             predominant antibody deficiency); b) phagocyte deficiency; c) complement factors\n             deficiency; d ) combined immunodeficiency including AIDS induced by HIV infection;\n             toxic, autoimmune, infectious, radial panleukopenia syndrome; general lymphocytopenia\n             syndrome; syndrome of lymphocyte polyclonal activation; postsplenectomia syndrome;\n             congenital asplenia; syndrome of immune complexes pathology associated with\n             infectious, allergic and autoimmune diseases.\n\n          4. Medical history of sarcoidosis.\n\n          5. Oncological diseases.\n\n          6. Exacebration or decompensation of chronic diseases affecting the patient's ability to\n             participate in the clinical trial.\n\n          7. Medical history of polyvalent allergy.\n\n          8. Allergy/ intolerance to any of the components of medications used in the treatment.\n\n          9. Impaired glucose tolerance, diabetes mellitus.\n\n         10. Hereditary fructose intolerance (as the study drug contains maltitol).\n\n         11. Intake of medicines listed in the section \"Prohibited concomitant treatment\" for 1\n             month prior to the inclusion in the trial.\n\n         12. Pregnancy, unwillingness of sexually active female patients to use of contraceptive\n             methods during the study.\n\n         13. Drug addiction, alcohol usage in the amount 2 units of alcohol per day  on the part\n             of patient's parents/adopters.\n\n         14. Mental disorders of patient or of patient's parents/adopters.\n\n         15. Patient's parents/ adopters, who from investigator's point of view,  will fail to\n             comply with the observation requirements of the trial or with the intake regimen of\n             the investigated medicines.\n\n         16. Participation in other clinical trials in the course of 3 months prior to the\n             inclusion in the trial.\n\n         17. Patient's parent/adopter is related to the research personnel of the investigative\n             site, who are directly involved in the trial or are the immediate relative of the\n             researcher. The immediate relatives includes husband/wife, parents, children or\n             brothers (or sisters), regardless of whether they are natural or adopted.\n\n         18. Patient's parent/adopter works for OOO \"NPF \"Materia Medica Holding\" (i.e. is the\n             company's employee, temporary contract worker or appointed official responsible for\n             the carrying out the research) or the immediate relative."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "306", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843842", 
            "org_study_id": "MMH-ER-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ergoferon (5 ml 3 times a day)", 
                "description": "Safety and Efficiency of liquid dosage form", 
                "intervention_name": "Ergoferon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (5 ml 3 times a day)", 
                "description": "Safety and Efficiency of liquid dosage form", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 24, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Alebai Sabitov, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ekaterinburg", 
                        "country": "Russian Federation", 
                        "zip": "620028"
                    }, 
                    "name": "Municipal Institution \"Child Health City Hospital \u211611\""
                }, 
                "investigator": {
                    "last_name": "Alebai Sabitov, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Natalia Geppe, MD, PhD, ScD, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119992"
                    }, 
                    "name": "State Educational Institution of Higher Professional Education \"Moscow State Medical Academy named after I.M. Sechenov\""
                }, 
                "investigator": {
                    "last_name": "Natalia Geppe, MD, PhD, ScD, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olga Shamsheva, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119049"
                    }, 
                    "name": "Morozovskaya Child Health City Clinical Hospital"
                }, 
                "investigator": {
                    "last_name": "Olga Shamsheva, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Elena Kondurina, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Novosibirsk", 
                        "country": "Russian Federation", 
                        "zip": "630091"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education Novosibirsk State Medical University of Ministry of Health of Russian Federation"
                }, 
                "investigator": {
                    "last_name": "Elena Kondurina, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olga Perminova, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Perm", 
                        "country": "Russian Federation", 
                        "zip": "614066"
                    }, 
                    "name": "Municipal Health Care Institution \"City Child Health Clinical Polyclinic \u21165\""
                }, 
                "investigator": {
                    "last_name": "Olga Perminova, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tatiana Pak, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194100"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education \"St. Petersburg State Pediatric Medical Academy\" of Ministry of Health of Russian Federation"
                }, 
                "investigator": {
                    "last_name": "Tatiana Pak, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olga Jiglinskaya, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "192212"
                    }, 
                    "name": "St. Petersburg State Budgetary Health Care Institution \"\u0421ity Polyclinic \u211644\""
                }, 
                "investigator": {
                    "last_name": "Olga Jiglinskaya, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrey Kamaev, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "191144"
                    }, 
                    "name": "State Budgetary Health Care Institution \"\u0421ity Child Health Polyclinic \u211644\""
                }, 
                "investigator": {
                    "last_name": "Andrey Kamaev, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Anna Galustyan, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194100"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education \"St. Petersburg State Pediatric Medical Academy\" of Ministry of Health of Russian Federation"
                }, 
                "investigator": {
                    "last_name": "Anna Galustyan, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Svetlana Laleko, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "196650"
                    }, 
                    "name": "State Health Care Institution \"Child Health City Hospital \u211622\""
                }, 
                "investigator": {
                    "last_name": "Svetlana Laleko, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Svetlana Lazareva, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194356"
                    }, 
                    "name": "Limited Liability Company \"Alliance Biomedical-Russian group\""
                }, 
                "investigator": {
                    "last_name": "Svetlana Lazareva, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Irina Melnikova, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation", 
                        "zip": "150000"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education \" Yaroslavl State Medical Academy\" of Ministry of Health"
                }, 
                "investigator": {
                    "last_name": "Irina Melnikova, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children", 
        "overall_contact": {
            "email": "PutilovskiyMA@materiamedica.ru", 
            "last_name": "Mikhail Putilovskiy, MD, PhD", 
            "phone": "+74957836804", 
            "phone_ext": "302"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Based on the data mentioned in a patient's diary", 
            "measure": "Proportion of patients demonstrating recovery/improvement in health", 
            "safety_issue": "No", 
            "time_frame": "On day 2, 3 and 4 of observation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dynamics of fever", 
                "safety_issue": "No", 
                "time_frame": "Changes in body temperature on day 2, 3, 4 and 5 of observation in comparison with the baseline"
            }, 
            {
                "measure": "Proportion of patients with normal body temperature (\u226437.0\u00ba\u0421)", 
                "safety_issue": "No", 
                "time_frame": "On day 2, 3, 4, 5 of observation"
            }, 
            {
                "description": "On day 3rd of observation based on the results of objective examination conducted by a physician; on days 2-5 - based on data mentioned in a patient's diary", 
                "measure": "Severity of clinical manifestations of acute respiratory infection (general symptoms and nasal/ throat/ chest symptoms) in scores", 
                "safety_issue": "No", 
                "time_frame": "On days 2-5 of observation"
            }, 
            {
                "description": "Based on data mentioned in a patient's diary", 
                "measure": "Duration of major clinical symptoms of acute respiratory infection (fever, general symptoms and nasal/ throat/ chest symptoms) in days", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Based on the data on area under curve for total index of severity of general symptoms and nasal/ throat/ chest symptoms on day 1, 3, 6 of observation - based on the results of objective examination conducted by a physician; on day 1, 2, 3, 4, 5 of the treatment - based on data mentioned in a patient's diary", 
                "measure": "The severity of acute respiratory infection course", 
                "safety_issue": "No", 
                "time_frame": "On day 1, 2, 3, 4, 5, 6 of the treatment"
            }, 
            {
                "description": "Based on data mentioned in a patient's diary", 
                "measure": "Number of intakes of antipyretics if indicated", 
                "safety_issue": "No", 
                "time_frame": "On day 1, 2, 3, 4 and 5 of the treatment"
            }, 
            {
                "description": "The development of disease complications requiring antibiotics administration or hospitalization", 
                "measure": "Proportion of patients with exacerbation of the disease course", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }
        ], 
        "source": "Materia Medica Holding", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Materia Medica Holding", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}